Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umeclidinium - GlaxoSmithKline

Drug Profile

Umeclidinium - GlaxoSmithKline

Alternative Names: 573719; Ellipta Incruse; Encruse Ellipta; GSK-573719; Incruse; Incruse Ellipta; UMEC; Umeclidinium bromide

Latest Information Update: 23 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Benzhydryl compounds; Bronchodilators; Quinuclidines; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma; Hyperhidrosis

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Hyperhidrosis(In volunteers, In adults) in Netherlands (Topical)
  • 24 Jun 2018 Biomarkers information updated
  • 16 Feb 2018 Pharmacokinetics, adverse events and efficacy data from a phase IIa trial in Palmar hyperhidrosis presented at the 76th Annual Meeting of the American Academy of Dermatology (AAD-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top